Niels Reinmuth1, Patrick Stumpf2, Andreas Stumpf2, Thomas Muley3, Sonja Kobinger4, Hans Hoffmann3, Felix J F Herth5, Philipp A Schnabel6, Helge Bischoff7, Michael Thomas7. 1. Department of Thoracic Oncology, Thoraxklinik at the University of Heidelberg, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg, German Center for Lung Research, Germany. Electronic address: N.Reinmuth@lungenclinic.de. 2. Department of Thoracic Oncology, Thoraxklinik at the University of Heidelberg, 69126 Heidelberg, Germany. 3. Department of Thoracic Surgery, Thoraxklinik at the University of Heidelberg, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg, German Center for Lung Research, Germany. 4. Department of Thoracic Surgery, Thoraxklinik at the University of Heidelberg, 69126 Heidelberg, Germany. 5. Department of Pneumology & Respiratory Critical Care Medicine, Thoraxklinik at the University of Heidelberg, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg, German Center for Lung Research, Germany. 6. Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany. 7. Department of Thoracic Oncology, Thoraxklinik at the University of Heidelberg, 69126 Heidelberg, Germany; Translational Lung Research Center Heidelberg, German Center for Lung Research, Germany.
Abstract
BACKGROUND: In the era of improving overall survival rates of malignant diseases, the impact of a previous malignancy (PM) on treatment and outcome of lung cancer (LC) remains unclear. METHODS: We reviewed all LC patients from our institution that were treated from 2004 to 2006 for the occurrence of LC with PM excluding patients with multiple primary LC. RESULTS: A total of 444 and 2698 LC patients with and without a history of a PM were identified (prevalence of 14.1%). PM were most often located in breast (15.5%), prostate (14.9%), bladder (9.0%) and kidney (8.8%). Compared to never smokers, patients with nicotine consumption had more often a cancer history of prostate, gastrointestinal, and the head-neck region. The median interval until diagnosis of LC was 72.2 months (range 0-537 months) with most LC diagnosed 5 years after PM diagnosis. With a similar distribution of histology, stage and localization compared to controls, NSCLC patients with PM and stage IV disease showed a favorable overall survival (p < 0.0001). In contrast, SCLC patients had similar survival curves (n.s.). CONCLUSIONS: A considerable subgroup of LC patients has a history of PM that may indicate a favorable prognostic factor. However, these patients should be treated similar to other LC patients.
BACKGROUND: In the era of improving overall survival rates of malignant diseases, the impact of a previous malignancy (PM) on treatment and outcome of lung cancer (LC) remains unclear. METHODS: We reviewed all LC patients from our institution that were treated from 2004 to 2006 for the occurrence of LC with PM excluding patients with multiple primary LC. RESULTS: A total of 444 and 2698 LC patients with and without a history of a PM were identified (prevalence of 14.1%). PM were most often located in breast (15.5%), prostate (14.9%), bladder (9.0%) and kidney (8.8%). Compared to never smokers, patients with nicotine consumption had more often a cancer history of prostate, gastrointestinal, and the head-neck region. The median interval until diagnosis of LC was 72.2 months (range 0-537 months) with most LC diagnosed 5 years after PM diagnosis. With a similar distribution of histology, stage and localization compared to controls, NSCLCpatients with PM and stage IV disease showed a favorable overall survival (p < 0.0001). In contrast, SCLCpatients had similar survival curves (n.s.). CONCLUSIONS: A considerable subgroup of LC patients has a history of PM that may indicate a favorable prognostic factor. However, these patients should be treated similar to other LC patients.
Authors: Darragh F Halpenny; Jane D Cunningham; Niamh M Long; Ramon E Sosa; Michelle S Ginsberg Journal: J Thorac Oncol Date: 2016-05-17 Impact factor: 15.609